Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn’s disease in clinical remission: a pilot study

BACKGROUND/AIMS: Fecal S100A12 (FS) and serum S100A12 (SS) have been reported as novel biomarkers that accurately reflect intestinal inflammation. We evaluated if FS and SS in comparison to fecal calprotectin (FC) are associated with poor future outcomes in clinically quiescent Crohn’s disease (CD)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sun-Ho, Hwang, Sung Wook, Park, Sang Hyoung, Yang, Dong-Hoon, Byeon, Jeong-Sik, Myung, Seung-Jae, Yang, Suk-Kyun, Ye, Byong Duk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081997/
https://www.ncbi.nlm.nih.gov/pubmed/35508954
http://dx.doi.org/10.5217/ir.2021.00020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081997/
https://www.ncbi.nlm.nih.gov/pubmed/35508954
http://dx.doi.org/10.5217/ir.2021.00020

Ejemplares similares